ArticleClinical rheumatology2025
Coronary periarteritis in IgG4-RD: A case series.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Acute coronary syndrome associated with probable immunoglobulin G4-related coronary periarteritis successfully treated with a drug-coated balloon.Journal of cardiology cases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIgG4-related disease (IgG4-RD) can affect multiple organ systems, with coronary artery involvement being rare. Coronary periarteritis may lead to complications such as myocardial infarction and ischemic cardiomyopathy. This case series characterizes the clinical and radiological features, complications, and treatment strategies in patients with IgG4-RD-associated coronary periarteritis.
methodsA retrospective review of the Mayo Clinic electronic health record identified 146 patients, of whom 9 met the inclusion criteria for IgG4-RD with coronary periarteritis. Clinical, laboratory, imaging, treatment, and outcome data were analyzed.
resultsThe cohort included 9 male patients (mean age: 55.5 ± 5.7 years). The median serum IgG-4 level was 282 mg/dL (interquartile range [IQR], 148-393), while the median C-reactive protein value was 10.8 mg/dL (IQR 7.5-53.6). The mean time from IgG4-RD diagnosis to coronary involvement was 2.5 years. CT angiography detected vessel wall thickening, affecting the right coronary artery (RCA) in five cases, the left anterior descending artery (LAD) in four, and the left main coronary artery in one. Aneurysm formation occurred in two cases. All patients received glucocorticoids, and seven were treated with rituximab. Over a mean follow-up of 7.5 years, one patient developed ischemic heart disease, and another progressed to heart failure. Repeat imaging showed partial or complete resolution of coronary thickening in seven patients.
conclusionCoronary artery involvement in IgG4-RD is rare but may lead to aneurysm formation and ischemic complications. CT and MRI are valuable diagnostic tools, and rituximab with glucocorticoids appears effective, though further studies are needed. Key Points • IgG4-related disease can involve the coronary arteries, leading to periarteritis and potential complications such as myocardial infarction and aneurysm formation, highlighting the need for early recognition. • Glucocorticoids and rituximab appear to be effective in managing IgG4-RD-associated coronary periarteritis, but further studies are needed to evaluate long-term outcomes.
Indexed as
Identifiers
40931286What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.